Molecular imaging of prostate cancer
Authors:
- 1 July 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 22 (4) , 320-327
Abstract
Purpose of review Prostate cancer is a complex and biologically heterogeneous disease that is not adequately assessed with conventional imaging alone. Molecular imaging with positron emission tomography (PET) is poised to fill this unmet need through noninvasive probing of the multiple molecular and cellular processes that are active in prostate cancer patients. Recent findings Several PET tracers are active in early-stage and late-stage prostate cancer in humans. F18-Fluorodeoxyglucose (FDG), C11/F18-choline and sodium F18-fluoride have been studied most extensively. There is a growing body of literature supporting the utility of choline in early-stage prostate cancer. FDG and sodium F18-fluoride are more valuable in advanced disease, especially for assessing bone metastases, the prevalent form of metastases in this patient population. F18-fluorodihydrotestosterone is active in castrate disease and is emerging as a valuable pharmacodynamic marker in the development of novel androgen receptor-targeted therapies. Prostate-specific membrane antigen PET tracers are in the early stages of clinical development. Summary Multiple PET tracers are currently available to aid in the detection and management of prostate cancer across the clinical spectrum of the disease. Prospective, rigorously controlled, clinical imaging trials are needed to establish the optimal role of PET in prostate cancer.Keywords
This publication has 43 references indexed in Scilit:
- Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CTJournal of Nuclear Medicine, 2011
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical PracticeJournal of Clinical Oncology, 2011
- 18F-fluorocholine for prostate cancer imaging: a systematic review of the literatureProstate Cancer and Prostatic Diseases, 2011
- 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In VivoJournal of Nuclear Medicine, 2010
- PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Clinical states in prostate cancer: toward a dynamic model of disease progressionUrology, 2000
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- The flare phenomenon on radionuclide bone scan in metastatic prostate cancerAmerican Journal of Roentgenology, 1984